{"identity":{"name":"Acme Therapeutics","slug":"acme-therapeutics","studyCount":1},"studies":[{"id":"STUDY-2025-001","code":"ONC-002","sponsor":"Acme Therapeutics","phase":"phase-2b","therapeuticArea":"Oncology","indication":"Relapsed/refractory multiple myeloma","status":"enrolling","health":"yellow","executiveSummary":"Single-arm dose-expansion of acemyebrelin in r/r multiple myeloma. Enrolment is tracking 12% behind plan due to slow activation at two EU sites; mitigation underway with two new US sites in start-up.","goals":["Confirm ORR ≥ 35% per IMWG in the 600 mg cohort","Maintain ≤ 10% Grade 3+ neutropenia at the expansion dose","Lock database within 90 days of LPLV","Deliver CSR within 120 days of database lock"],"kpis":[{"label":"Enrolment","value":"88 / 120 (73%)","delta":"-12% vs plan","deltaDirection":"down","threshold":"at-risk"},{"label":"Screen failure rate","value":"34%","delta":"+4 pts","deltaDirection":"up","threshold":"at-risk"},{"label":"Query aging (>14d)","value":"47 open","delta":"+8","deltaDirection":"up","threshold":"at-risk"},{"label":"Protocol deviations","value":"23","delta":"+2","deltaDirection":"up","threshold":"on-target"},{"label":"Projected DBL variance","value":"+28 days","deltaDirection":"up","threshold":"at-risk"},{"label":"Budget burn","value":"68%","delta":"+3 pts","deltaDirection":"up","threshold":"on-target"},{"label":"Forecast EAC","value":"$18.4M","delta":"+$0.6M","deltaDirection":"up","threshold":"at-risk"}],"milestones":[{"id":"fpi","name":"FPI","plannedDate":"2024-09-15","actualOrForecastDate":"2024-10-02","status":"complete"},{"id":"enrol-25","name":"25% enrolment","plannedDate":"2025-02-15","actualOrForecastDate":"2025-03-10","status":"complete"},{"id":"enrol-50","name":"50% enrolment","plannedDate":"2025-06-30","actualOrForecastDate":"2025-07-22","status":"complete"},{"id":"enrol-75","name":"75% enrolment","plannedDate":"2025-11-30","actualOrForecastDate":"2026-01-15","status":"in-progress"},{"id":"lpi","name":"LPI","plannedDate":"2026-04-15","actualOrForecastDate":"2026-05-30","status":"at-risk"},{"id":"lplv","name":"LPLV","plannedDate":"2026-10-15","actualOrForecastDate":"2026-11-30","status":"planned"},{"id":"dbl","name":"Database lock","plannedDate":"2027-01-15","actualOrForecastDate":"2027-02-12","status":"planned"},{"id":"csr-draft","name":"CSR draft","plannedDate":"2027-03-15","actualOrForecastDate":"2027-04-12","status":"planned"},{"id":"csr-final","name":"CSR final","plannedDate":"2027-05-15","actualOrForecastDate":"2027-06-12","status":"planned"}],"timeline":{"startDate":"2024-09-15","plannedEndDate":"2027-05-15","currentForecastEndDate":"2027-06-12"},"risks":[{"id":"r1","title":"EU site activation delayed by competent authority backlog","owner":"Regulatory Lead","severity":"high","mitigation":"Escalated; two replacement US sites in qualification (target activation +45d).","status":"mitigating"},{"id":"r2","title":"Higher than expected screen failure on creatinine clearance criterion","owner":"Medical Monitor","severity":"medium","mitigation":"Protocol amendment v3 in draft to relax CrCl from 60 to 50 mL/min.","status":"open"},{"id":"r3","title":"CRO sub-contracting central lab going through M&A","owner":"CRA Manager","severity":"medium","mitigation":"Continuity letter on file; back-up lab identified.","status":"mitigating"},{"id":"r4","title":"Investigator turnover at top-3 enrolling site","owner":"CRA Manager","severity":"low","mitigation":"Sub-investigator certified and trained.","status":"closed"}],"resources":[{"role":"CRA","headcount":6,"fte":4.5,"ratePerMonth":18500},{"role":"Data Management","headcount":3,"fte":2.4,"ratePerMonth":15200},{"role":"Pharmacovigilance","headcount":2,"fte":1,"ratePerMonth":17800},{"role":"Biostatistics","headcount":2,"fte":1.2,"ratePerMonth":22000},{"role":"Medical Writing","headcount":1,"fte":0.5,"ratePerMonth":19500}],"financials":{"contractedBudget":17800000,"ebvSpent":12104000,"eacBudget":18400000,"currency":"USD"},"recentActivityCounts":{"provenanceLast24h":412,"stagingPending":7,"signaturesLast7d":24}}],"metrics":{"totalEvents30d":0,"sites":6,"enrollment":88,"requestsOpen":0,"signaturesIssued30d":0,"openRisks":3,"criticalRisks":0}}